Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
MicroRNA29 : A Mechanistic Contributor and Potential Biomarker in Atrial Fibrillation
:
A Mechanistic Contributor and Potential Biomarker in Atrial Fibrillation
Beschreibung:
<jats:sec>
<jats:title>Background—</jats:title>
<jats:p>Congestive heart failure (CHF) causes atrial fibrotic remodeling, a substrate for atrial fibrillation (AF) maintenance. MicroRNA29 (miR29) targets extracellular matrix proteins. In the present study, we examined miR29b changes in patients with AF and/or CHF and in a CHF-related AF animal model and assessed its potential role in controlling atrial fibrous tissue production.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods and Results—</jats:title>
<jats:p>
Control dogs were compared with dogs subjected to ventricular tachypacing for 24 hours, 1 week, or 2 weeks to induce CHF. Atrial miR29b expression decreased within 24 hours in both whole atrial tissue and atrial fibroblasts (−87% and −92% versus control, respectively;
<jats:italic>p</jats:italic>
<0.001 for both) and remained decreased throughout the time course. Expression of miR29b extracellular matrix target genes collagen-1A1 (COL1A1), collagen-3A1 (COL3A1), and fibrillin increased significantly in CHF fibroblasts. Lentivirus-mediated miR29b knockdown in canine atrial fibroblasts (−68%;
<jats:italic>p</jats:italic>
<0.01) enhanced COL1A1, COL3A1, and fibrillin mRNA expression by 28% (
<jats:italic>p</jats:italic>
<0.01), 19% (
<jats:italic>p</jats:italic>
<0.05), and 20% (
<jats:italic>p</jats:italic>
<0.05), respectively, versus empty virus–infected fibroblasts and increased COL1A1 protein expression by 90% (
<jats:italic>p</jats:italic>
<0.05). In contrast, 3-fold overexpression of miR29b decreased COL1A1, COL3A1, and fibrillin mRNA by 65%, 62%, and 61% (all
<jats:italic>p</jats:italic>
<0.001), respectively, versus scrambled control and decreased COL1A1 protein by 60% (
<jats:italic>p</jats:italic>
<0.05). MiR29b plasma levels were decreased in patients with CHF or AF (by 53% and 54%, respectively; both
<jats:italic>p</jats:italic>
<0.001) and were further decreased in patients with both AF and CHF (by 84%;
<jats:italic>p</jats:italic>
<0.001). MiR29b expression was also reduced in the atria of chronic AF patients (by 54% versus sinus rhythm;
<jats:italic>p</jats:italic>
<0.05). Adenoassociated viral–mediated knockdown of miR29b in mice significantly increased atrial COL1A1 mRNA expression and cardiac tissue collagen content.
</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions—</jats:title>
<jats:p>MiR29 likely plays a role in atrial fibrotic remodeling and may have value as a biomarker and/or therapeutic target.</jats:p>
</jats:sec>